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Public health and the 
knowledge industry
Saúde pública e indústria do 
conhecimento
ABSTRACT
Knowledge plays an important role in health care. The production and diffusion 
of health-related knowledge are increasingly under the control of private 
commercial interests, which are characterized by confl icts of interests that 
result in abuses of power. Considerable research has been done on the medical-
industrial complex and its role in the production of power imbalances and the 
consequent abuses, but little attention has been dedicated to the role played 
by the publishing industry, which can be subject to the same problems. The 
widely diffused idea that “frequent and major changes” occur in medicine, 
albeit unsupported by clearcut evidence, is an effective marketing tool for 
both the pharmaceutical and publishing industries, who feed and thrive on 
physicians’ insecurities. The production and distribution of knowledge should 
be addressed as a strategic component of public health.
DESCRIPTORS: Knowledge. Scientific and Technical Publications. 
Publication Bias. Scientifi c Communication and Diffusion. Scientifi c 
Misconduct. Health Care Sector.
RESUMO
O conhecimento desempenha papel importante no cuidado em saúde. A 
produção e difusão do conhecimento em saúde estão atualmente cada vez mais 
sob controle de interesses comerciais privados, caracterizados por confl itos de 
interesses que resultam em abusos de poder. Embora esforços consideráveis 
tenham sido dedicados ao estudo do complexo médico-industrial e seu papel 
na produção de tais desequilíbrios de poder e abusos conseqüentes, pouca 
atenção tem sido dada ao papel desempenhado pela indústria de publicação, 
que pode estar sujeita aos mesmos problemas. A idéia amplamente difundida 
de que “mudanças importantes e freqüentes” ocorrem na medicina, ainda que 
sem claro apoio em evidências, é uma ferramenta de marketing efetiva das 
indústrias farmacêutica e de publicação, que se alimentam da insegurança dos 
médicos. A produção e distribuição do conhecimento deveriam ser abordadas 
como um componente estratégico da saúde pública.
DESCRITORES: Conhecimento. Publicações Científi cas e Técnicas. Viés de 
Publicação. Comunicação e Divulgação Científi ca. Má Conduta Científi ca. 
Setor de Assistência à Saúde.
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A recently published commentary22 strongly denounced 
how previous US government policies improperly 
undermined the fi ndings of solid research in order to 
further a political agenda. The basic principle defended 
by the authors is clear: sound public policy requires 
sound science, and the latter is being artifi cially desta-
bilized by political actions. That threatens the public’s 
trust in public policies in general. In the authors’ words, 
“The legitimacy, authority, credibility, and acceptability 
of our public policies depend on the public’s trust in the 
validity of the processes that produced them.”22:1939
Unfortunately, the slogan “sound science” was 
hijacked by parties interested in anything but sound 
science,20 since it threatens their bottom line, as is 
demonstrated in the many papers that compose a 2005 
supplement of the American Journal of Public Health. 
In its editorial,18 Michaels underlined the problems 
created, when judges evaluate the validity of scientifi c 
evidence, and how those problems are exploited by 
powerful litigants with inevitable repercussions in 
terms of public policy. The editorial made explicit 
reference to manufactured controversies around scien-
tifi c knowledge (a gambit that became so widespread 
it earned the neologism, manufactroversy). An issue 
Another paper in the same supplement17 expanded on 
how that strategy was repeatedly used to trump proper 
regulatory policies intended to protect public health, 
with the tobacco industry being the most notorious 
case. The political maneuvering of the tobacco industry 
in order to compromise effective regulation is the 
subject of two other papers in the supplement.4,8
Many of the risks, to the integrity of the scientifi c 
enterprise and to the implementation of effective public 
health policy, are summarized in yet another paper in 
that supplement,30 suggestively titled “The Perils of 
Relying on Interested Parties to Evaluate Scientifi c 
Quality”. Whereas the preceding authors describe a 
strategy of undermining good science for political or 
fi nancial gain, I would like to point out that the same 
motivations could lead to hastily labeling problematic 
knowledge as established science. In a sense, most of 
the assessment of scientifi c quality in health is being 
delegated to fi nancially interested parties. The thesis I 
am trying to establish is that the ever growing commer-
cialization (and commodification) of knowledge 
inherently poses increased health risks for the general 
population. Biomedical knowledge was singled out for 
this exercise given its core role in public health; medical 
care is a key component to public health in many ways, 
including in terms of total health expenditure.
Health interventions, be they at an individual level 
through a physician interacting with a patient or at 
a community level through public health policies, 
INTRODUCTION
depend on trusted bodies of knowledge. Those bodies 
of knowledge may not determine the interventions,6 but 
at the very least they play a key role in the decision-
making process that leads to concrete actions and play 
a key role in justifying decisions in the public arena, 
when necessary. The trusted status of such bodies of 
knowledge is the result of an unstable equilibrium; new 
knowledge, quite often at odds with previously accepted 
truths, is constantly generated by ongoing research. This 
is a complex process, which demands resources and 
dedication, with a group of experts – scientists – being 
in charge. The expert scientists produce knowledge and 
assure its quality, while average physicians are users 
of this knowledge, and the physicians rely in varying 
degrees on the expertise of scientists for the reliability 
of the statements. This does not mean that doctors have 
it easy keeping up with the moving target of knowledge 
and with the demanding and time-consuming activities 
of the profession. The changing knowledge base creates 
yet another reason why they have to rely on second-
hand, when it comes to knowledge validity claims.6 
Yet, accurate, up-to-date knowledge, is a major asset 
to them, not only for informing their actions but also 
for maintaining their professional identity; in the end, 
what separates proper doctors from quacks is precisely 
the ownership and mastery of their specifi c body of 
knowledge.
This puts physicians in a bind: they depend on a product 
– knowledge – the production and quality of which 
they do not control.
MANUFACTURING BIOMEDICAL 
KNOWLEDGE
The establishment of a fact in medicine depends upon 
human power and material resources on a scale that only 
a handful of major players can fund. The pharmaceut-
ical companies are key players and have a clear interest 
in doctors prescribing their new drugs at some point.
This creates a major potential for problems – euphem-
istically called “confl icts of interest” – which have 
been the subject of intense debates over the last two 
decades.15,19 Regardless of the ongoing debate and 
attempts by numerous editors to reign in confl icts of 
interest, the current state of affairs is still far from satis-
factory, as Chalmers, the past director of the Cochrane 
Centre, recently noted.7
Symptomatically, a slew of books was recently 
published within months of each other,1-3,13 addressing 
(or, more precisely, decrying) the innumerable prob-
lems that arise from the dominance of commercial 
interests in the production of medical knowledge. As 
one of those authors accurately states, “the role of 
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a Dingley B. U. S. Periodical Prices -2005. Chicago: American Library Association; 2005[cited 2007 Mar 20]. Available from: http://www.ala.
org/ala/alctscontent/alctspubsbucket/alctsresources/general/periodicalsindex/05USPPI.pdf
the drug and medical-device companies has evolved 
so that their most important product is ‘scientifi c 
evidence.’ This is what drives sales.”1:94
Each one of those authors analyzes and exposes diffe-
rent aspects of the array of institutions, agents and inte-
rests that gravitate around health care, a conglomerate 
aptly labeled the medical-industrial complex. Problems, 
distortions and outright ethical (if not criminal) viola-
tions take place in the development of new drugs, new 
technologies, their approval and dissemination. Among 
their examples are strategies that include purposefully 
distorting experimental data in order to obtain a favo-
rable result; propping up of key medical fi gures as 
endorsers of new drugs; the production of papers by 
ghost writers, which are simply signed by presumably 
respectable researchers; the various gifts provided to 
doctors (Reidy20 provides a detailed account of those 
strategies from the point of view of a pharmaceutical 
sales rep); lobbying to weaken or bypass government 
regulation; control of the content of continued medical 
programs and so on and so forth.
What is important to stress is that those problems are 
more or less unavoidable given the current state of 
affairs. There is a power struggle over the validity of 
certain statements, and as long as one of the contenders 
is the proverbial eight hundred pound gorilla and no 
effective checks-and-balances are in place, the outcome 
is predictable. No matter how skeptical doctors may 
be of claims from the industrial side of the medical-
industrial complex, given the disproportionate amount 
of resources available to the latter, in the end, doctors 
have no choice but to submit.5:849 This point is also 
made in different ways by the mentioned authors. 
Abramson states that “although many doctors have a gut 
feeling that there is a pro-industry bias in the scientifi c 
evidence that guides their care, almost all the infor-
mation that comes their way, including the opinions 
of the experts they trust, reinforces the validity of this 
‘knowledge’”.1:97 Besides, Avorn3 wrote that “as long 
as the nation continues to allow most clinical research 
on drugs to be conducted by and for the companies that 
manufacture these products, who stand to gain or lose 
literally billions of dollars over their results, we are not 
going to get all the answers we need to our questions 
about drug effi cacy and safety... or feel secure that the 
right questions are even being asked”.3:xiii-xiv The issue 
is not so much research funding –a favorite argument 
of the pharmaceutical industry in justifying high drug 
prices and patents– but the control of the results. For 
Goozner10 and Angell2 a much higher proportion of 
medical research funding comes from government 
or other non-profi t sources than generally thought. 
Nevertheless, commercial interests (including those 
of universities, who were allowed from the eighties 
onwards to patent drugs even when they received gover-
nment funding for the basic research behind the patent 
claim) manage to control the production of knowledge 
and present to the public an exaggerated version of their 
role in its development.
SELLING KNOWLEDGE
Knowledge is an abstract product, but it depends on 
some kind of material support in order to effectively 
circulate. Committing knowledge to paper creates a 
knowledge product, and once the printing takes place, 
we have a material product mirroring the abstract one.
The justifi ed concern with the abstract part of the 
process has left the material expressions of knowledge 
practically unexamined. Far from being a neutral 
battleground, specialized journals and books have a 
very active role in the establishment of what counts as 
“scientifi c evidence” and a commercial dimension of 
their own, which often add to the more easily perceived 
issues dealt with in the previous section.
Although there are many journals and books, the 
relevant publishers are relatively few, and their total 
number has been decreasing over time as a result of 
mergers that have occurred in the publishing industry 
over the last decades. This has created some concern 
about the effects of concentration on the circulation 
of ideas and its associated costs.27 Another reason 
for concern is the embarrassing connections of such 
publishing conglomerates with other types of busi-
nesses. As a recent paper from the British Medical 
Journal states, “in a recent editorial in the Journal of 
the Royal Society of Medicine, Richard Smith drew 
attention once again to the paradoxical and disturbing 
association between Reed Elsevier, a huge global 
publishing company, and the international arms 
trade”.31:547 Although relentless pressure from the global 
scientifi c community eventually led Elsevier’s parent 
company to withdraw from that line of business, it is 
still an embarrassment that it took so long.
In concentrated and specialized markets, competition 
is not price-based but relies on product differentiation. 
An example concerning the medical publishing industry 
can be derived from an analysis of the U.S. Periodical 
Price Index 2005.a The price of subscriptions to medical 
journals is ranked third highest on average and had the 
highest average increase over ten years. Medical books 
are notoriously expensive, even when compared with 
similar publications.
Proof of the importance placed on product differentia-
tion is the value attached to artifi cial measurements 
of a journal’s importance, particularly on the impact 
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factor. Although even its creator, Garfi eld, clearly 
criticized its use in evaluation exercises,9 and criticism 
has mounted over its usage being extended beyond 
reasonable use.24
Attempts to restrict the adoption of new technologies 
that might threaten the dominance of the current major 
players are another important consequence of this type 
of market. In the case of publishing, this is represented 
by the dazzling new possibilities presented by the 
internet as a means to disseminate information. The 
reaction one of the most important medical journals, 
The New England Journal of Medicine (NEJM), to the 
new technology is quite telling. In an editorial origin-
ally published in 1995, the then editor of the NEJM 
obliquely stated that sending a paper through e-mail 
to more than two dozen people would confi gure prior 
publication and thus void it from submission to the 
NEJM.12 This policy is still in place Contrast that with 
the practises of the physics community, where general 
availability of preprints is the norm, and papers are 
published only after being available online for a while 
and thus strengthened by vigorous debate. This differ-
ence is addressed in Kassirer’s editorial, who attributes 
the more stringent policies of medical journals to the 
need to protect the general population from widespread 
adoption of poorly grounded knowledge that could 
threaten their health. Considering the numerous and 
recurring problems created by papers that nevertheless 
passed the gatekeeping processes of journal publishing, 
one has to wonder if that argument has any merit.
Taking the preceding discussion into account, it should 
be clear by now that the medical publishing industry 
is an integral part of the medical-industrial complex, 
and thus affected by the same confl icts and problems 
that have been extensively documented with regards 
to its more visible pharmaceutical and medical equip-
ment counterparts.
WHEN RESEARCH AND MARKETING 
STRATEGIES CONVERGE
An infl uential manual on evidence-based medicine 
states in its initial pages that “new types of evidence are 
now being generated which, when we know and under-
stand them, create frequent, major changes in the way 
that we care for our patients”.23:5 This idea is repeated 
over and over by different sources, and the evidence 
presented for it is usually the gargantuan volume of 
papers printed every year by medical journals, already 
unmanageable as it is and increasing geometrically 
in numbers. But does this confi rm the existence of 
“frequent, major changes” in medical knowledge?
Let us consider one specifi c segment of that knowledge, 
drug usage. The pharmaceutical industry would vigor-
ously endorse the assumption of a quickly changing 
medical landscape; a pamphlet, downloadable from 
their website,a opens with the following sentence: 
“Over the past decade, pharmaceutical companies 
have pushed the scientifi c envelope, working at the 
cellular and molecular levels to dramatically advance 
the treatment of disease. At the end of 2002, 28% 
more medicines were being investigated by pharma-
ceutical companies for approval by the Food and Drug 
Administration (FDA) than was true one decade before. 
More than 1,000 medicines are now in the development 
pipeline.” However, as both Goozner10 and Angell2 
point out, the majority of those drugs are the so-called 
“me-too” drugs. These substances do not represent 
major pharmaceutical innovations but small modifi ca-
tions of already existing products, in order to join the 
bandwagon of a commercially successful chemical or 
to get extended patent protection.2,10 A 2002 study by 
the National Institute for Health Care Management 
stated that “highly innovative drugs – medicines that 
contain new active ingredients and also provide signifi -
cant clinical improvement – are rare. Over the 12-year 
period examined, just 153 out of a total of 1,035 new 
drug approvals (or 15%) were for such drugs, priority-
rated NMEs [New Molecular Entity]. Lipitor, Viagra, 
Fosamax, Avandia, Actos, and Plavix were among the 
drugs in this category. By contrast, drugs providing 
modest innovation are common. In 1989–2000, 472 
new drugs or 46% of the total approved were standard 
IMDs [Incrementally Modifi ed Drug]”.28:3
Some disheartening signs have also emerged concerning 
the content of what is published. In an editorial on PLoS/
Medicine (incidentally, an open-access journal), Smith, 
previously editor of the British Medical Journal for 25 
years, vigorously denounced the publishing of clinical 
trials as nothing but a marketing tool for the pharma-
ceutical industry.25 Not long after that, the same journal 
published a dozen articles on disease mongering, that is, 
the industry-sponsored “discovery” of new diseases (or 
the extension of already known ones) that coincidently 
could help the sales of specifi c drugs. Papers on erectile 
dysfunction,16 female sexual dysfunction29 and bipolar 
disorder11 are among the most remarkable.
Steinman et al were able to detail the multi-pronged 
marketing strategy of the pharmaceutical industry 
through a case study on gabapentin based on internal 
documents obtained through litigation.26 In their conclu-
sion, they write that “research, publications, and educa-
tional programs (including ‘independent’ events) were 
used as marketing opportunities, augmented by opinion 
leaders and local physician champions to engage their 
physician colleagues”.26:290
a The Pharmaceutical Research and Manufacturers of America. A decade of innovation: advances in the pharmaceutical treatment of disease. 
Washington; 2003[cited 2007 abr 16]. Available from: http://www.phrma.org/fi les/Decade_of_Innovation.pdf
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These actions are complemented through vigorous 
advertising of prescription drugs to the general public 
through the poorly disguised formula of “ask your 
doctor about...”, a strategy that has already been 
demonstrated as having the industry’s desired effects 
on prescription patterns.14
It seems, then, that while it is safe to assume that 
there are indeed frequent or major changes in medical 
knowledge, the major changes are not frequent and 
vice-versa. The only supporting evidence of that claim 
is the sheer volume of medical publications, but this 
volume says nothing for the quality, timeliness or 
necessity of the content being published and can more 
easily be attributed to the drive of “publish or perish” 
policies than anything else. The academic job market 
and the evaluation of research grants has been increas-
ingly reliant on bibliometric evaluations. The goal is not 
just publishing anywhere, but in the high impact factor 
journals or in books by the most prestigious publishers, 
which in turn are controlled by a small number of 
companies and so on and so forth. Again, market logic 
creates its self-vindication.
The “frequent, major change” myth and the epic output 
of the publishing industry, however, have a very defi nite 
effect with important economic implications: they feed 
and thrive on doctors’ insecurity. Doctors feel constantly 
threatened that they and their knowledge will become 
obsolete at any moment and that only exhaustive efforts 
will help them keep abreast in this sea of change; yet 
they will never completely succeed.
This creates a pliable market for both the pharmaceut-
ical and publishing industries. Insecure practitioners 
will willingly pay the rising prices of already expensive 
journal subscriptions (or books that have a limited shelf 
life, or subscribe to equally expensive online services) 
in order to allay their fear of obsolescence. Quite likely 
they will not have the time and/or resources to read 
through the mounting piles of papers, but will only 
perfunctorily scan some of those, selectively looking 
at abstracts and often literally jumping to conclusions. 
This reinforces their reverence for the epistemic 
authority of the people, who wrote those papers, and 
makes them more susceptible to the claims and strat-
egies of the pharmaceutical representatives swarming 
around medical offices or to continuing medical 
education programs that are little more than a front for 
the same industry. Commercial interests– that have 
demonstrated over and over again that they cannot be 
trusted to self-regulate – are in control of the full cycle 
of production and distribution of medical knowledge, 
with dire consequences in terms of costs and quality 
of health care.
CONCLUSIONS
The old adage, knowledge is power, still holds true. To 
it I would add a corollary: those who control knowledge 
are the most powerful of all.
It should be clear by now that knowledge is as much 
an essential to public health as vaccines or screening 
tests are, and should thus be treated accordingly. The 
production and circulation of medical knowledge 
should be unburdened from commercial interests that 
do not necessarily align with the interests of health care 
professionals or the general population. When those sets 
of interests confl ict, the outcome in the current climate 
is easily predictable.
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